IMUGEN Reference Diagnostic Division
Oxford Immunotec, Inc. d/b/a IMUGEN
315 Norwood Park South, Norwood MA 02062 • [redacted]

Laboratory Results

Submitter:

WOODSON C MERRELL MD
SUITE 1B
44 EAST 67TH STREET
NEW YORK, NY 10065

Ordering Provider: WOODSON C MERRELL MD

Account #: MERW

Patient:

Name: JEFFREY EPSTEIN
Address: 9 EAST 71ST STREET
NEW YORK, NY 10021

D.O.B.: 1/20/1953

Submitter Record #:

IMUGEN Patient #: 2018013061

Babesia microti Serology

PLASMA #: 13061
PLASMA Collection Date: 09/14/2018
PLASMA Receipt Date: 09/17/2018

Test Method: Indirect immunofluorescence

Test Date: 09/17/2018

Antigen	Antibody Isotype	Result
B. microti	IgG	<32

Result is the reciprocal of the plasma endpoint dilution.
Normal Range is a titer <32 (1:32 dilution): Negative.

Test Method: Immunoblot (Western Blot)

Test Date: 09/17/2018

Antigen	Antibody Isotype	Result
B. microti	IgG	NEGATIVE
B. microti	IgM	NEGATIVE

Normal Range for IgG Western blot: No reactivity to at least one of three specific protein bands (at 42, 38 and 30KDa): Negative.

Normal Range for IgM Western blot: No reactivity to at least one of four specific protein bands (at 45, 42, 38 and 30KDa): Negative.

Comments: No IgG antibody to *B. microti* detected by indirect immunofluorescence or by immunoblot. No IgM antibody detected by immunoblot.

Interpretation: No serologic evidence of infection with *B. microti*.

Note 1: Results should be evaluated in conjunction with clinical presentation and other medical and diagnostic findings.
Note 2: A negative result does not exclude the possibility of infection with *B. microti*. The immune response may not have developed at the time of sample collection. The CDC recommends that individuals whose exposure could have occurred on the West Coast should be tested also for antibodies to *Babesia duncani*, because of the lack of cross-reactivity with *B. microti*.
Note 3: A positive result is not definitive evidence of infection with *B. microti*. Infection with *Plasmodium falciparum* can cause a positive response.
Note 4: These tests were developed and their performance characteristics determined by IMUGEN. They have not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. These tests are used for clinical purposes. They should not be regarded as investigational or for research.

Report Date: 09/18/2018 MR

Mihae Platt M.D., Ph.D. Director
CLIA number 22D0650196